- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 5, 2024Jake Holdreith Named to Twin Cities Business Top 100
-
December 4, 2024Robins Kaplan Obtains $10.5 Million Post-Verdict in Landmark Aerosol Dust Remover Abuse Case
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking Q2
July 16, 2024
This quarterly issue of the GENERICally Speaking campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
In this issue:
- Amarin Pharma, Inc. v. Hikma Pharms. USA Inc.
Vascepa® (icosapent ethyl)
Because plaintiff plausibly pled that, despite its section viii carve-out, defendant had induced infringement of the asserted patents, defendant is not entitled to dismissal at the Rule 12 motion stage. - Salix Pharms., Ltd. v. Norwich Pharms. Inc.
Xifaxan® (rifaximin)
The Federal Circuit affirmed the obviousness of two sets of patents, but also affirmed the denial of generic manufacturer’s Rule 60 motion seeking to carve out an infringing indication in its ANDA after the district court entered judgment of infringement and validity as to patents covering that indication. - Janssen Pharms., Inc. v. Teva Pharms. USA, Inc.
Invega Sustenna® (paliperidone palmitate)
Because the district court applied a more rigid obviousness analysis that that prescribed by KSR, and because claim scope was to “a” patient and not a population of patients, finding of invalidity on the basis of obviousness was vacated and remanded. - Janssen Pharms., Inc. v. Tolmar, Inc.
Invega Sustenna® (paliperidone palmitate)
The Federal Circuit vacating a finding of non-obviousness of an identical patent by another district court did not lead to reconsideration of this court’s finding of non-obviousness because this court applied the reasoning that the Federal Circuit laid out in its opinion while it considered the issue of obviousness at trial. - Teva Branded Pharm. Products R&D, Inc. v. Amneal Pharms. of NY, LLC
ProAir® HFA (albuterol sulfate)
Defendants’ motion for judgment on the pleadings seeking patent delisting from FDA’s Orange Book was granted when the patents did not claim the drug for which the applicant submitted the application or a drug product. - Pharmacyclics LLC v. Alvogen Pine Brook LLC
Imbruvica® (ibrutinib)
Because both parties were vexatious in their litigation conduct, the court denied plaintiffs’ motion for attorneys’ and experts’ fees.
Relevant ANDA Updates highlighted in this issue:
Vascepa® (icosapent ethyl)
ProAir® HFA (albuterol sulfate)
Imbruvica® (ibrutinib)
Xifaxan® (rifaximin)
Invega Sustenna® (paliperidone palmitate)
Invega Sustenna® (paliperidone palmitate)
New Drug Applications and 505(b)(2) Applications
Reported settlements in federal district court cases
Abbreviated New Drug Applications and 505(b)(2) Applications
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.